Novavax (NVAX) Cash from Operations (QoQ) (2010 - 2026)
Powered by 
Analysis
Novavax (NVAX) Cash from Operations (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Novavax | 1.67 Bn | 949.38 Mn | 42.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -124.55% |
| Mar 31, 2026 | 17.78% |
| Dec 31, 2025 | -136.59% |
| Sep 30, 2025 | 184.55% |
| Jun 30, 2025 | 31.29% |
| Mar 31, 2025 | -7.13% |
| Dec 31, 2024 | -19.58% |
| Sep 30, 2024 | -146.08% |
| Jun 30, 2024 | 476.12% |
| Mar 31, 2024 | 52.74% |
| Dec 31, 2023 | -345.80% |
| Sep 30, 2023 | 76.94% |
| Jun 30, 2023 | 47.19% |
| Mar 31, 2023 | -176.36% |
| Dec 31, 2022 | -204.37% |
| Sep 30, 2022 | 77.35% |
| Jun 30, 2022 | -93.09% |
| Mar 31, 2022 | 74.15% |
| Dec 31, 2021 | -140.89% |
| Sep 30, 2021 | -198.43% |